1. Home
  2. SBGI vs ERAS Comparison

SBGI vs ERAS Comparison

Compare SBGI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$15.53

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$15.28

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
ERAS
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
SBGI
ERAS
Price
$15.53
$15.28
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$21.80
$7.20
AVG Volume (30 Days)
398.7K
3.4M
Earning Date
05-26-2026
01-01-0001
Dividend Yield
6.46%
N/A
EPS Growth
N/A
16.87
EPS
N/A
N/A
Revenue
$3,169,000,000.00
N/A
Revenue This Year
$12.59
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.89
$1.01
52 Week High
$17.88
$16.00

Technical Indicators

Market Signals
Indicator
SBGI
ERAS
Relative Strength Index (RSI) 55.79 75.80
Support Level $14.43 $1.46
Resistance Level $15.62 N/A
Average True Range (ATR) 0.76 0.86
MACD 0.10 0.05
Stochastic Oscillator 57.46 81.55

Price Performance

Historical Comparison
SBGI
ERAS

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: